Similarly, bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, has been found to possess immunomodulatory properties, as VEGF exerts immunosuppressive functions via inhibiting dendritic cell maturation and T-cell tumor infiltration. The gene discussed is VEGFA; the disease is neoplasm.